AIM: To observe the efficacy of intravitreal injection with ranibizumab combined with laser photocoagulation for macular edema(ME)secondary to macular branch retinal vein occlusion(MBRVO).

METHODS: A retrospective analysis included 33 patients(33 eyes)with ME secondary to MBRVO were taken. All patients received intravitreal injection of 0.5mg ranibizumab(0.05ml)at first visit. The continue PRN treatment and laser photocoagulation were based on the visual acuity changes and optical coherence tomography findings. The changes of best corrected visual acuity(BCVA), central macular thickness(CMT), and amplitude density and latency of P1 wave in mfERG were observed before treatment and 6mo after treatment.

RESULTS: Before the treatment, logMAR was 0.68±0.35, 6mo after treatment was 0.34±0.23, BCVA was improved obviously(P<0.01), BCVA in 21 patients(63.64%)were improved in two rows among all the patients. CMT before treatment was(487.30±63.58)μm, after treatment was(238.84±52.66)μm(P<0.01). The amplitude densities of P1 wave in ring 1, ring 2 and ring 3 after treatment were significantly increased(all P<0.01), and the latencies were decrease(all P<0.05). The conjunctival hemorrhage was observed in 2 eyes after treatment.

CONCLUSION: Intravitreal injection with ranibizumab combined with laser photocoagulation for ME secondary to MBRVO can reduce the CMT and improve visual function.